A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer.

Trial Profile

A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Mar 2012 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University; PCYC0405CA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top